Product Information
ARISTADA ER 662 MG/2.4 ML SYRN is a brand product labeled by Alkermes, Inc., priced at $1006.5742 per ML under NDC 65757040203. Its NADAC has been published 520 times since Oct 19, 2016.
FDA first approved this application on Oct 5, 2015.
Strength
662 mg/2.4mL
Manufacturer
Alkermes, Inc.NDC
65757040203
Classification
Brand
Dosage Form
INJECTION, SUSPENSION, EXTENDED RELEASE
Route
INTRAMUSCULAR
Effective Date
9/23/2026
Active Ingredients
ARIPIPRAZOLE LAUROXILApproval Type
New Drug (NDA)
FDA Application
NDA207533FDA Approved
10/5/2015
On Market Since
10/5/2015
Pharmacological Classes
Price Statistics
The NADAC for ARISTADA ER 662 MG/2.4 ML SYRN has been published 520 times since Oct 19, 2016, and over the history we have for it it has risen 53.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1006.5742 per ML |
|---|---|
| All-time high | $1007.8450 (Sep 16, 2026) |
| All-time low | $655.3550 (Oct 19, 2016) |
| 52-week high | $1007.8450 |
| 52-week low | $943.9397 |
| Median price | $845.4223 |
| Average price | $834.6211 |
| Largest weekly change | +6.0% (Apr 15, 2020) |
| Weeks tracked | 520 |
| Tracking since | Oct 19, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the aripiprazole lauroxil market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alkermes, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
aripiprazole lauroxil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ARISTADA ER 662 MG/2.4 ML SYRN?
The current National Average Drug Acquisition Cost (NADAC) for ARISTADA ER 662 MG/2.4 ML SYRN, manufactured by Alkermes, Inc., is $1006.5742 per ML (NDC 65757040203), effective Sep 30, 2026.
How has the price of ARISTADA ER 662 MG/2.4 ML SYRN changed over time?
Over the history we have for it, the NADAC for ARISTADA ER 662 MG/2.4 ML SYRN has risen 53.6%. It has been tracked across 520 weekly CMS publications since Oct 19, 2016.
What are the highest and lowest recorded NADAC prices for ARISTADA ER 662 MG/2.4 ML SYRN?
Since Oct 19, 2016, the NADAC for ARISTADA ER 662 MG/2.4 ML SYRN has ranged from a low of $655.3550 (Oct 19, 2016) to a high of $1007.8450 (Sep 16, 2026), with a median of $845.4223 per ML.
Are there cheaper alternatives to ARISTADA ER 662 MG/2.4 ML SYRN?
No other NADAC-published product currently shares the active ingredient and strength of ARISTADA ER 662 MG/2.4 ML SYRN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ARISTADA ER 662 MG/2.4 ML SYRN?
ARISTADA ER 662 MG/2.4 ML SYRN (NDC 65757040203) is labeled by Alkermes, Inc., and CMS classifies it as a brand product.